AB 2246 amends Section 26000.5 of California's Business and Professions Code to preserve two existing rules through January 1, 2028: (1) licensed cannabis manufacturers may use cannabinoid concentrates and extracts only if those inputs were manufactured or processed exclusively from cannabis sourced from a licensed cannabis cultivator; and (2) licensees may not possess, transport, distribute, manufacture, or sell industrial hemp on licensed premises, except that licensed testing laboratories may test industrial hemp.
On paper the bill is a nonsubstantive edit, but its practical effect is to keep strict sourcing and on-premises hemp prohibitions in force for the near term. That matters to manufacturers, cultivators, hemp producers, and testing labs because it preserves existing traceability and market-access constraints that determine who can supply cannabinoid inputs and how hemp-derived products can be handled in California's regulated market.
At a Glance
What It Does
The bill requires licensed cannabis manufacturers to use only cannabinoid concentrates and extracts produced exclusively from cannabis obtained from licensed cultivators. It also forbids licensees from having industrial hemp on licensed premises in any form, with an explicit exception allowing licensed testing laboratories to test hemp. Both rules apply until January 1, 2028.
Who It Affects
Licensed cannabis manufacturers and their sourcing teams, licensed cultivators who supply concentrates, industrial-hemp growers and processors seeking access to California's legal market, and licensed cannabis testing laboratories. Compliance officers at licensed premises must enforce the prohibitions and document supplier provenance.
Why It Matters
The measure locks in a supply-chain boundary that preserves traceability and limits hemp-derived cannabinoid inputs in the regulated cannabis market. That creates continued market protection for cultivators and constrains hemp-based product pathways and procurement strategies for manufacturers and handlers.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
AB 2246 leaves intact two tightly linked provisions of California’s cannabis licensing regime and sets a deadline for their continued application. First, manufacturers cannot accept or use cannabinoid concentrates or extracts unless those inputs were manufactured or processed exclusively from cannabis that itself was obtained from a licensed cannabis cultivator.
The word “exclusively” functions as a bright-line delimiter: inputs originating (in whole or part) from non-licensed sources—including industrial hemp supply chains—are excluded from use in licensed manufacturing.
Second, the statute bars any licensee from having industrial hemp on licensed premises in any capacity: possession, transport, distribution, manufacture, or sale. The only narrow carve-out permits a licensed testing laboratory to test industrial hemp.
That exception is limited in scope; the statute does not authorize hemp-based manufacturing, distribution, or retailing on a licensed cannabis site—only testing activity tied to a licensed lab.Operationally, those rules keep California’s regulated cannabis product supply chained to the state’s licensed cultivator base and force procurement, documentation, and track-and-trace practices that prove source provenance. For manufacturers that had considered sourcing hemp-derived cannabinoids or mixes, the statute leaves little room for hybrid inputs.
For testing labs, the law preserves an explicit but contained role in analyzing hemp samples while denying most licensed businesses the ability to host hemp materials on-site.Finally, both provisions are explicitly temporary: they apply only until January 1, 2028. That sunset creates a fixed planning horizon for industry and regulators, but while active the provisions sustain current market boundaries and enforcement responsibilities without creating new statutory penalties or compliance mechanisms beyond the existing licensing framework.
The Five Things You Need to Know
The statute requires that any cannabinoid concentrates or extracts used by a licensed manufacturer be manufactured or processed exclusively from cannabis obtained from a licensed cannabis cultivator—no partial or mixed sourcing from unlicensed hemp is permitted.
Licensees may not possess, transport, distribute, manufacture, or sell industrial hemp on licensed premises; the prohibition lists five discrete prohibited activities rather than a single general ban.
Licensed testing laboratories are the sole exception: they may test industrial hemp, which implicitly permits limited possession of hemp samples for testing purposes at a lab facility.
Both the manufacturer-sourcing requirement and the hemp-on-premises prohibition are expressly limited in duration and remain in effect only until January 1, 2028.
AB 2246 is presented as a nonsubstantive amendment—it does not add new enforcement penalties or create new licensing categories; it preserves and clarifies existing statutory boundaries.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Temporary applicability through January 1, 2028
The section opens by making both subparts time-limited: their force ends on January 1, 2028. For compliance teams and counsel, the practical implication is a known sunset that should be treated as a planning milestone for procurement strategy, contract terms, and any regulatory petitions or administrative guidance that stakeholders may seek before that date.
Source restriction for cannabinoid concentrates and extracts
Subsection (a) compels licensed manufacturers to accept only cannabinoid concentrates and extracts that were manufactured or processed exclusively from cannabis obtained from licensed cultivators. That exclusivity language closes off mixed-source inputs: a concentrate that incorporates hemp-derived intermediates or any material not traceable to a licensed cultivator would not qualify. Practically, manufacturers must collect and retain supplier documentation and rely on California’s track-and-trace tools to demonstrate compliance during inspections or audits.
Industrial hemp ban on licensed premises with lab testing carve‑out
Subsection (b) imposes a blanket prohibition on licensees possessing, transporting, distributing, manufacturing, or selling industrial hemp on licensed premises, enumerating specific prohibited activities rather than leaving the clause open-ended. The only explicit exception allows licensed testing laboratories to test industrial hemp, which authorizes labs to possess hemp samples for analytical purposes but does not permit hemp manufacturing, distribution, or retail activity at a cannabis licensed site. Enforcement will hinge on how regulators interpret the scope of 'testing' and what counts as a licensed laboratory's premises.
This bill is one of many.
Codify tracks hundreds of bills on Agriculture across all five countries.
Explore Agriculture in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Licensed cannabis cultivators — preserving an exclusive supply channel for concentrates and extracts reduces competition from industrial-hemp processors who might otherwise supply cannabinoid inputs.
- Regulators and public-safety officials — maintaining a closed, traceable supply chain simplifies oversight and reduces the risk of noncompliant hemp-derived material entering the regulated cannabis market.
- Licensed cannabis testing laboratories — the statutory exception explicitly allows them to handle hemp for testing, preserving business for labs qualified to analyze hemp samples under license.
- Licensed manufacturers that already source from licensed cultivators — they keep predictable supplier relationships and avoid supply-chain disruption from new hemp entrants.
Who Bears the Cost
- Industrial-hemp growers and processors — the prohibition prevents them from bringing hemp onto licensed cannabis premises and limits routes to market inside California’s regulated cannabis system.
- Manufacturers considering hemp-derived cannabinoid inputs — they must forgo hemp as a source for concentrates and extracts in licensed manufacturing, constraining product formulation options.
- Compliance officers and licensees — they must maintain rigorous provenance documentation, update supplier contracts, and enforce physical segregation to avoid inadvertent possession or transport of hemp.
- Non-licensed or out-of-state testing providers — only licensed California cannabis testing labs get the explicit testing exception, potentially excluding other service providers from testing opportunities on licensed premises.
Key Issues
The Core Tension
The central dilemma is preserving a tightly traceable, licensed cannabis supply chain to protect consumer safety and regulatory oversight versus allowing hemp-derived inputs and market innovation broader access to the regulated market; tightening supply rules secures traceability but constrains commerce and may incentivize alternative, less-regulated pathways.
The statute’s language creates several implementation questions that regulators and industry must resolve administratively. First, the term “exclusively” will drive disputes: what level of supplier documentation suffices to prove that a concentrate was processed only from cannabis sourced from a licensed cultivator?
Traceability systems will need to link upstream processing records to final concentrates; absent clear guidance, inspections could lead to inconsistent enforcement. Second, the testing-lab exception is narrow on its face but vague in practice.
The law permits testing of industrial hemp by licensed labs, but it does not define how long samples may be stored, whether secondary processing for testing preparation is allowed, or whether off-site couriering of samples counts as transport by a licensee.
There is also a market-design trade-off: the rule protects the integrity of the regulated cannabis supply chain but may push hemp-derived innovation into unregulated channels or out-of-state markets, with potential downstream consumer-safety and tax-revenue implications. Finally, the sunset date reduces but does not eliminate uncertainty: businesses must plan around a known termination point, which could spur short-term strategic shifts (contracting, inventory stockpiling, or litigation) as January 1, 2028 approaches unless regulators provide transitional guidance well in advance.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.